Abstract:Abstract IMPORTANCE Genetic diseases are a leading cause of childhood mortality. Whole genome sequencing (WGS) and whole exome sequencing (WES) are relatively new methods for diagnosing genetic diseases. OBJECTIVES Compare the diagnostic sensitivity (rate of causative, pathogenic or likely pathogenic genotypes in known disease genes) and rate of clinical utility (proportion in whom medical or surgical management was changed by diagnosis) of WGS, WES, and chromosomal microarrays (CMA) in children with suspected genetic diseases. DATA SOURCES AND STUDY SELECTION Systematic review of the literature (January 2011 - August 2017) for studies of diagnostic sensitivity and/or clinical utility of WGS, WES, and/or CMA in children with suspected genetic diseases. 2% of identified studies met selection criteria. DATA EXTRACTION AND SYNTHESIS Two investigators extracted data independently following MOOSE/PRISMA guidelines. MAIN OUTCOMES AND MEASURES Pooled rates and 95% Cl were estimated with a random-effects model. Metaanalysis of the rate of diagnosis was based on test type, family structure, and site of testing. RESULTS In 36 observational series and one randomized control trial, comprising 20,068 children, the diagnostic sensitivity of WGS (0.41, 95% Cl 0.34-0.48, I 2 =44%) and WES (0.35, 95% Cl 0.31-0.39, I 2 =85%) were qualitatively greater than CMA (0.10, 95% Cl 0.08-0.12, I 2 =81%). Subgroup meta-analyses showed that the diagnostic sensitivity of WGS was significantly greater than CMA in studies published in 2017 ( P <.0001, I 2 =13% and I 2 =40%, respectively), and the diagnostic sensitivity of WES was significantly greater than CMA in studies featuring within-cohort comparisons ( P <001, I 2 =36%). Evidence for a significant difference in the diagnostic sensitivity of WGS and WES was lacking. In studies featuring within-cohort comparisons of singleton and trio WGS/WES, the likelihood of diagnosis was significantly greater for trios (odds ratio 2.04, 95% Cl 1.62-2.56, I 2 =12%; P <.0001). The diagnostic sensitivity of WGS/WES with hospital-based interpretation (0.41, 95% Cl 0.38-0.45, I 2 =50%) was qualitatively higher than that of reference laboratories (0.28, 95% Cl 0.24-0.32, I 2 =81%); this difference was significant in meta-analysis of studies published in 2017 ( P =.004, I 2 =34% and I 2 =26%, respectively). The rates of clinical utility of WGS (0.27, 95% Cl 0.17-0.40, I 2 =54%) and WES (0.18, 95% Cl 0.13-0.24, I 2 -77%) were higher than CMA (0.06, 95% Cl 0.05-0.07, I 2 =42%); this difference was significant in meta-analysis of WGS vs CMA ( P <.0001). CONCLUSIONS AND RELEVANCE In children with suspected genetic diseases, the diagnostic sensitivity and rate of clinical utility of WGS/WES were greater than CMA. Subgroups with higher WGS/WES diagnostic sensitivity were trios and those receiving hospital-based interpretation. WGS/WES should be considered a first-line genomic test for children with suspected genetic diseases. Key Points Question What is the relative diagnostic sensitivity and clinical utility of different genome tests in children with suspected genetic diseases? Findings Whole genome sequencing had greater diagnostic sensitivity and clinical utility than chromosomal microarrays. Testing parent-child trios had greater diagnostic sensitivity than proband singletons. Hospital-based testing had greater diagnostic sensitivity than reference laboratories. Meaning Trio genomic sequencing is the most sensitive diagnostic test for children with suspected genetic diseases.

Real-world diagnostic outcomes and cost-effectiveness of genome-wide sequencing for developmental and seizure disorders: evidence from Canada

Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature

Utility of genome sequencing in exome‐negative pediatric patients with neurodevelopmental phenotypes

Narrowing the Diagnostic Gap: Genomes, Episignatures, Long-Read Sequencing and Health Economic Analyses in an Exome-Negative Intellectual Disability Cohort

Cost-effectiveness of exome sequencing and chromosomal microarray for low-risk pregnancies: Cost-effectiveness of Prenatal Exome Sequencing

Utility of next generation sequencing in paediatric neurological disorders: experience from South Africa

Whole-Genome vs Whole-Exome Sequencing in Suspected Genetic Disorders

High Diagnostic Yield and Clinical Utility of Next-Generation Sequencing in Children with Epilepsy and Neurodevelopmental Delays: A Retrospective Study

Utility of Genome Sequencing After Nondiagnostic Exome Sequencing in Unexplained Pediatric Epilepsy

Genome Sequencing Demonstrates High Diagnostic Yield in Children with Undiagnosed Global Developmental Delay/intellectual Disability: A Prospective Study

Diagnostic and Clinical Utility of Whole Genome Sequencing in a Cohort of Undiagnosed Chinese Families with Rare Diseases

A meta-analysis of the diagnostic sensitivity and clinical utility of genome sequencing, exome sequencing and chromosomal microarray in children with suspected genetic diseases

The performance of genome sequencing as a first-tier test for neurodevelopmental disorders

Rapid Genome Sequencing Compared to a Gene Panel in Infants with a Suspected Genetic Disorder: An Economic Evaluation

Clinical exome sequencing as the first-tier test for diagnosing developmental disorders covering both CNV and SNV: a Chinese cohort

Comparison of medical management and genetic counseling options pre- and post-whole exome sequencing for patients with positive and negative results.

Enhanced utility of family-centered diagnostic exome sequencing with inheritance model–based analysis: results from 500 unselected families with undiagnosed genetic conditions

Meta-analysis of the diagnostic and clinical utility of genome and exome sequencing and chromosomal microarray in children with suspected genetic diseases

Using medical exome sequencing to identify the causes of neurodevelopmental disorders: Experience of 2 clinical units and 216 patients

Exome sequencing identifies molecular diagnosis in children with drug-resistant epilepsy

Clinical Application of Targeted Next-Generation Sequencing Panels and Whole Exome Sequencing in Childhood Epilepsy